Core Viewpoint - The article discusses the challenges faced by Huaxi Biological, particularly its declining performance and the strategic changes initiated by its founder Zhao Yan to revitalize the company after a period of poor financial results [5][19]. Financial Performance - In the first three quarters of 2025, Huaxi Biological reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [5]. - The decline in profit is attributed to the drop in revenue from the skin science innovation transformation business, previously known as functional skincare products [5][10]. - Despite the overall decline, there was a notable improvement in the second quarter of 2024, with net profit increasing by 20.89% year-on-year, marking the first growth since the second quarter of 2024 [5][6]. Strategic Changes - Zhao Yan returned to the operational front line in March 2024, initiating a comprehensive reform of the company's management, sales expenses, and strategic direction [5][19]. - The company has reduced its sales expense ratio to 34.26%, the lowest in five years, by cutting costs in marketing and promotional activities [6]. - Huaxi Biological is undergoing a transformation process that includes organizational restructuring, talent system adjustments, and marketing model innovations [7][19]. Market Context - The medical beauty market is rapidly changing, with Huaxi Biological's market value dropping significantly from nearly 150 billion yuan at its peak in July 2021 to 25.977 billion yuan by October 29, 2024 [9]. - The stock price has also seen a dramatic decline, falling over 82% from its historical high of 312.99 yuan per share [9][10]. - The emergence of collagen peptide products has shifted investor focus away from hyaluronic acid, leading to a decline in Huaxi Biological's market position [12][13]. Competitive Landscape - Other companies in the hyaluronic acid sector, such as Haohai Biological and Aimeike, have also experienced significant stock price declines, indicating a broader trend in the market [11]. - New entrants focusing on collagen products have gained traction, with companies like Juzhibio and Jinbo Biological reporting substantial revenue growth, further challenging Huaxi Biological's market share [12][13]. Product Performance - The functional skincare product line, once a growth driver, has seen revenue declines exceeding 15% year-on-year in recent quarters, significantly impacting overall performance [6][13]. - The revenue from key brands like Runbaiyan and Kuaidi has also decreased, with projections indicating further declines in 2024 [21].

Core Viewpoint - Jinbo Bio's revenue and net profit growth have slowed down following the challenge to its exclusive status in the "medical device three certificates" market, with the company reporting a significant decline in net profit for the third quarter of 2025 [2][3]. Financial Performance - For the first three quarters of 2025, Jinbo Bio reported revenue of 1.296 billion yuan, a year-on-year increase of 31.1%, and a net profit of 568 million yuan, up 9.29% year-on-year [2]. - In the third quarter of 2025, revenue was 437 million yuan, reflecting a year-on-year growth of 13.36%, while net profit decreased by 16.24% to 176 million yuan, marking the first quarterly net profit decline since the company's listing [2]. - The company's stock price fell by 7.07% to 245.5 yuan per share as of October 30, 2025, nearly a 50% drop since May of the same year [2]. Product and Market Dynamics - Wei Yimei, a key product of Jinbo Bio, has consistently contributed over 80% to the company's revenue, with its core component being recombinant humanized collagen, which is a Class III medical device approved by the National Medical Products Administration [3]. - Jinbo Bio held three "medical device three certificates" for recombinant collagen products, which have been crucial for its high growth, with revenue increasing from 102 million yuan in the first half of 2021 to 859 million yuan in the first half of 2025, representing a compound annual growth rate of 69.9% [3]. - The exclusive market position of Jinbo Bio has been challenged by the recent approval of a "medical device three certificate" for a competing product from Juzi Bio, marking the entry of additional players into the recombinant collagen market [3][4]. Competitive Landscape - Other leading medical aesthetic companies are also applying for "medical device three certificates" in the recombinant collagen sector, including Chuangjian Medical and Huaxi Bio, indicating increasing competition [4]. - Jinbo Bio's management stated that the company still possesses three certificates as technical support and maintains advantages in technology accumulation and product matrix in the recombinant collagen implant market [4]. Business Segmentation - Jinbo Bio's revenue growth is attributed to both medical devices and functional skincare products, with the latter seeing a significant increase of 152% in revenue growth in the first half of 2025 [5]. - The contribution of medical devices to Jinbo Bio's revenue decreased from 88% in the first half of 2024 to 82.5% in the first half of 2025, while the share of functional skincare products rose from 8% to 14% [5].

Investment Rating - The investment rating for the company is "Outperform the Market" [1][14]. Core Views - The approval of the company's first injectable recombinant collagen type I medical device marks a significant breakthrough in the aesthetic medicine sector, opening a new growth curve for the company [2][3]. - Despite short-term sales fluctuations due to market reactions to the Double 11 shopping festival, the company is expected to perform well in the latter half of the event, supported by its established offline medical institution channels and brand influence [2][14]. - The management's continuous share buybacks signal strong long-term confidence in the company's prospects [2][13]. Summary by Sections Company Overview - The company announced on October 23, 2025, that its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber" received the Class III medical device registration certificate from the National Medical Products Administration (NMPA) [2][3]. - This product is the first approved drug-device combination in the company's Class III medical device pipeline, indicating a strategic expansion into the high-barrier aesthetic injection device market [3]. Product Details - The product is a white or off-white sponge-like solid composed of recombinant type I α1 collagen, with various specifications ranging from 10mg to 24mg per bottle [5]. - It is indicated for facial dermal tissue filling to correct dynamic wrinkles, including forehead lines, glabellar lines, and crow's feet [5]. Market Potential - The domestic market currently has 12 approved Class III collagen medical devices, with only four related to recombinant collagen, highlighting the uniqueness of the company's product [4]. - The collagen injection market is projected to reach approximately 9.8 billion by 2025, indicating significant growth potential for the company [7]. Financial Projections - The company is expected to achieve net profits of 2.549 billion, 3.092 billion, and 3.673 billion for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 15, 12, and 10 [2][14]. - The management's share buybacks have increased their stake to 54.66%, reflecting confidence in the company's future performance [13]. Competitive Landscape - The company's recombinant type I collagen differs from competitors' type III collagen, suggesting a non-direct competition scenario that could enhance its market position [7]. - The approval of additional products in the pipeline is anticipated to accelerate, further strengthening the company's market presence [8].

Core Insights - The 2025 Hurun Rich List reveals a significant increase in the number of Chinese billionaires, with 1,434 individuals having wealth exceeding 5 billion yuan, marking a 31% year-on-year growth [3] - The total wealth of the listed billionaires reached nearly 30 trillion yuan, an increase of 9 trillion yuan, representing a growth rate of 42% compared to the previous year [3] - The beauty industry has shown resilience, with notable entries such as Mao Geping and his wife, who debuted on the list with a wealth of 20.5 billion yuan, and the founder of Up Beauty, Lü Yixiong, whose wealth surged by 16 billion yuan [4][5] Industry Overview - The growth in total wealth is largely attributed to a significant recovery in the stock market, with major indices like the Shanghai Composite Index and the Hang Seng Index rising by 40-50% compared to the previous year [4] - The beauty industry, while not traditionally a wealth accumulation powerhouse, has demonstrated positive trends despite market volatility, with key players like Giant Biological and Mao Geping showing substantial wealth increases [4][9] - The beauty sector is undergoing a transformation characterized by "hard technology replacing traffic dividends," indicating a shift in business strategies within the industry [6] Notable Individuals - The couple Fan Daidi and Yan Jianya from Giant Biological topped the beauty sector with a wealth of 33 billion yuan, reflecting a 35% increase from the previous year [4][5] - Mao Geping and his wife ranked 9th among new entrants with a wealth of 20.5 billion yuan, highlighting their prominence in the beauty industry [5][9] - Lü Yixiong, founder and CEO of Up Beauty, saw his wealth increase by over 50 billion yuan, making him the richest in the cosmetics sector [13] Market Dynamics - The wealth rankings in the beauty industry have experienced significant fluctuations, with some founders seeing their wealth decrease due to stock market volatility [13][17] - The market capitalization of Giant Biological has seen a dramatic decline, impacting the wealth of its founders, while other companies like Mao Geping have shown resilience in their market performance [15][17] - The competitive landscape in the beauty industry remains intense, with the wealth of top entrepreneurs reflecting the ongoing capital-driven dynamics of the sector [18]

Core Viewpoint - The company has received approval for its recombinant type I α1 collagen freeze-dried fibers, marking a significant advancement in its medical aesthetics segment and enhancing its product portfolio [1] Group 1: Product Approval - The product "recombinant type I α1 collagen freeze-dried fibers" has been approved by NMPA on October 21, with registration number 20253132049, making it the first recombinant type I natural sequence collagen injection product in China [1] - The product is characterized as a white or off-white sponge-like solid composed of recombinant type I α1 collagen, utilizing a specific amino acid sequence of 753 amino acids [1] - It is indicated for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] Group 2: Financial Forecast - The company is projected to achieve net profits attributable to the parent company of 2.52 billion, 3.16 billion, and 3.81 billion yuan for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 22.2%, 25.3%, and 20.5% [2] - The recombinant collagen segment is expected to experience high growth potential, especially following the recent approval of the medical aesthetics product, which may provide significant marginal catalytic elasticity [2] - The company maintains a "buy" rating despite recent challenges faced by its cosmetics brand due to public opinion events [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The approval of three types of medical devices opens up growth opportunities in the medical beauty sector [2] - The company has successfully obtained NMPA approval for its recombinant type I α1 collagen freeze-dried fibers, marking a significant advancement in its product offerings [5] - The company is expected to see substantial profit growth, with projected net profits of 2.52 billion, 3.16 billion, and 3.81 billion RMB for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 22.2%, 25.3%, and 20.5% [5] Financial Forecast and Valuation - Closing price as of October 24, 2023, is HKD 41.68, with a market capitalization of HKD 44.64 billion [4] - Revenue projections are as follows: 3,524.1 million RMB in 2023, 5,538.8 million RMB in 2024, 6,997.89 million RMB in 2025, 8,693.63 million RMB in 2026, and 10,420.60 million RMB in 2027, with corresponding growth rates of 49.0%, 57.2%, 26.3%, 24.2%, and 19.9% [4] - The company’s return on equity (ROE) is projected to decline from 33.3% in 2023 to 23.0% in 2027, while the price-to-earnings (P/E) ratio is expected to decrease from 21.81 in 2023 to 10.7 in 2027 [4]

Investment Rating - The report suggests to pay attention to Jinbo Biological's ongoing developments in the collagen protein application field, indicating a positive outlook for the company [1] Core Viewpoints - Jinbo Biological is actively responding to the demand in China's health industry by expanding its product matrix. The company has made significant moves recently, including the launch of new products and strategic partnerships [2][5] - The company has successfully registered its "recombinant type III humanized collagen freeze-dried fiber" as a pharmaceutical excipient, marking a major breakthrough in high-end biomedical materials [7] - Jinbo Biological's functional skincare brands have shown impressive sales growth during the recent "Double Eleven" shopping festival, with a notable increase in revenue from its proprietary brands [12] - The overall market for consumer services on the Beijing Stock Exchange has seen a median price increase of 2.14% in stock prices, indicating a positive trend in the sector [15][18] - The TTM median price-to-earnings ratio for the broader consumer industry has increased to 56.3X, reflecting a growing valuation in the sector [27][30] Summary by Sections Jinbo Biological's Expansion - Jinbo Biological is expanding its product applications in response to the health industry demand, with a focus on collagen products and strategic partnerships with companies like Yangshengtang [2][10] - The company has established a national-level intellectual property operation center for functional proteins, enhancing its competitive edge in the recombinant collagen market [5][6] Market Performance - The median stock price change for consumer service companies on the Beijing Stock Exchange was +2.14%, with 31 out of 39 companies experiencing stock price increases [15][18] - The total market capitalization for consumer service companies rose from 1140.72 billion to 1143.84 billion, indicating a healthy market environment [20][22] Industry Valuation - The TTM median price-to-earnings ratio for the consumer sector has increased from 55.1X to 56.3X, suggesting a positive valuation trend [27][30] - Specific sectors such as food and beverage, as well as professional technical services, have also seen increases in their TTM median price-to-earnings ratios, indicating overall growth in the consumer market [29][32] Announcements - The successful launch of a 150,000 tons/year n-butane maleic anhydride production facility by Ruihua Technology demonstrates advancements in production technology and reinforces its leading position in the industry [35][37]

Core Insights - Furuida Pharmaceutical Co., Ltd. reported a revenue of 2.597 billion yuan and a net profit of 142 million yuan for the first three quarters of 2025, indicating overall performance pressure but signs of recovery in its cosmetics segment [1] Group 1: Cosmetics Business Performance - The cosmetics segment generated revenue of 1.569 billion yuan, a year-on-year decline of 8.17%, but maintained a high gross margin of 61.24%, reflecting strong profitability [1] - The Yilian brand achieved sales of 786 million yuan from January to September, a year-on-year increase of 19.50%, with its core spray product line generating 664 million yuan, up 28%, serving as a key growth driver [1] - The Aier Doctor brand showed signs of recovery with sales of 646 million yuan in the first three quarters, and the decline in the third quarter significantly narrowed [1] Group 2: Brand Development and Market Positioning - Yilian successfully held its first brand culture communication conference, enhancing brand influence and market recognition [1] - Aier Doctor hosted the sixth Microecological Health Conference, reinforcing its research image in the skin microecology field, laying the groundwork for future market recovery [1] Group 3: Emerging Brands and R&D Initiatives - The Koying brand demonstrated high growth potential with sales of 77.19 million yuan in the first three quarters, with sequential growth rates of 82% and 138% in the second and third quarters, respectively [2] - The company continues to invest in R&D, launching the industry's first ideal skin data platform based on ideal skin microbiome research and AI models [2] - The company led the establishment of a group standard for collagen penetration and degradation detection, which has been officially implemented [2] Group 4: Medical Device and Raw Material Performance - The medical device registration progressed with the sodium hyaluronate repair solution receiving product registration, and three Class II medical device certificates obtained in the first three quarters, supporting future expansion in functional skincare and medical aesthetics [2] - The raw materials and additives segment performed steadily, achieving revenue of 276 million yuan, a year-on-year increase of 11.19%, with a gross margin rising to 40.26% [2] - The pharmaceutical segment reported revenue of 305 million yuan, a year-on-year decline of 17.46%, with the company responding by increasing academic promotion and developing new food-medicine homologous products [2]

Investment Rating - The industry rating is "Overweight" (maintained) [6] Core Insights - The report highlights that the beauty and personal care industry has shown a relative return of -2.84% over the past month, -13.54% over the past three months, and -14.02% over the past year compared to the CSI 300 index [3] - The report notes that the newly approved recombinant type I collagen products by Juzhi Biotech are expected to enhance market competition, with various specifications available [6] - The report emphasizes the strong performance of brands like Han Shu and Proya during the "Double 11" shopping festival, indicating robust consumer demand [6] Summary by Sections Industry Performance - The beauty and personal care sector has experienced a relative return of -2.84% in the last month, -13.54% in the last three months, and -14.02% in the last year compared to the CSI 300 index [3] Product Developments - Juzhi Biotech's recombinant type I collagen has been approved, with product specifications ranging from 10mg to 24mg per bottle, primarily used for facial dermal filling to correct dynamic wrinkles [6] - The report mentions that the recombinant collagen market is seeing new entrants, with Juzhi Biotech and Jinbo Biotech being key players [6] Market Trends - Data from Q3 2025 shows that the GMV for the beauty category on Douyin grew by 19.69% year-on-year, with Han Shu leading with over 500 million in GMV [6] - The report indicates that Proya has consistently ranked first in the Tmall beauty category for three consecutive years, with expectations to maintain this position in 2025 [6] Investment Recommendations - The report suggests monitoring Juzhi Biotech's marketing strategies and sales performance for its new collagen products [6] - It recommends focusing on leading domestic skincare companies like Proya and Shanghai Jahwa, as well as other listed companies in the collagen sector [6]

Core Viewpoint - CICC maintains the profit forecast for Giant Bio (02367) for 2025-2026, with the current stock price corresponding to a P/E of 16/13x for those years, and sets a target price of HKD 70, indicating a potential upside of 68% based on the approval of medical beauty products and the recovery of the cosmetics business [1] Company Status - On October 23, Giant Bio announced that its "Recombinant Type I α1 Collagen Lyophilized Fiber" medical device has been approved, marking it as China's first recombinant Type I natural sequence collagen facial injection product [2][3] Product Approval and Market Potential - The approved product is indicated for facial tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet. The market for recombinant collagen injectables is still considered a blue ocean, and the company is expected to benefit from first-mover advantages, with potential revenue from this product projected to reach around RMB 1 billion in the long term [3] Commercialization Preparation - The company has made substantial preparations for commercialization, including team building and initial communication with doctors and institutions. As of the first half of 2025, it has covered approximately 1,700 public hospitals and 3,000 private hospitals and medical beauty clinics, leveraging its existing sales experience and brand operation capabilities to enhance product visibility and market promotion [4] Future Pipeline and Growth Opportunities - The company has a rich pipeline of future products, including non-crosslinked hydrating products currently in the registration phase, crosslinked neck wrinkle products that have received priority review status, and crosslinked nasolabial fold products progressing smoothly. The approval of the first medical beauty product validates the company's technological leadership and safety, with further pipeline developments expected to broaden the growth trajectory. Additionally, the cosmetics business is anticipated to improve gradually with the recovery of promotional activities [5]